AxoGen, Inc. (AXGN) Given Average Recommendation of “Buy” by Brokerages
Shares of AxoGen, Inc. (NASDAQ:AXGN) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $29.33.
Several equities research analysts have commented on AXGN shares. Leerink Swann boosted their target price on AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, November 21st. Lake Street Capital boosted their target price on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Wedbush restated a “buy” rating and issued a $27.00 target price (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. BidaskClub cut AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of AxoGen in a research note on Friday, January 5th.
In other news, Director Jamie Mark Grooms sold 21,290 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Guido J. Neels sold 1,150,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,293,990 shares of company stock worth $26,494,898. Company insiders own 9.33% of the company’s stock.
Shares of AxoGen (NASDAQ AXGN) opened at $24.90 on Friday. The company has a market capitalization of $831.89, a P/E ratio of -62.25 and a beta of 0.12. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95. AxoGen has a 12 month low of $9.55 and a 12 month high of $31.70.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/axogen-inc-axgn-given-average-recommendation-of-buy-by-brokerages/1857187.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.